| 刘旭辉,钱文浩,方 翔,王 勇,周 耀,徐瑞婷.替格瑞洛联合瑞舒伐他汀钙片对冠心病患者心功能、凝血功能及基质金属蛋白酶的影响[J].,2020,(15):2967-2970 |
| 替格瑞洛联合瑞舒伐他汀钙片对冠心病患者心功能、凝血功能及基质金属蛋白酶的影响 |
| Effects of Ticagrelor Combined with Risuvastatin Calcium Tablets on the Cardiac Function, Blood Coagulation Function and Matrix Metalloproteinase in the Patients with Coronary Heart Disease |
| 投稿时间：2019-12-28 修订日期：2020-01-23 |
| DOI：10.13241/j.cnki.pmb.2020.15.034 |
| 中文关键词: 冠心病 替格瑞洛 凝血功能 心功能 基质金属蛋白酶 |
| 英文关键词: Coronary heart disease Ticagrelor Coagulation function Cardiac function Matrix metalloproteinase |
| 基金项目:江苏省青年医学重点人才培养基金项目(QNRC2016422) |
|
| 摘要点击次数: 507 |
| 全文下载次数: 278 |
| 中文摘要: |
| 摘要 目的：探究替格瑞洛联合瑞舒伐他汀钙片及阿司匹林对冠心病患者心功能、凝血功能及基质金属蛋白酶的影响。方法：选择2015年7月～2018年12月于我院心内科接受治疗的77例冠心病患者，按患者是否服用替格瑞洛将其分为替格瑞洛组和对照组。对照组在常规西药治疗方法上服用阿司匹林和瑞舒伐他汀钙片，替格瑞洛组在对照组的治疗方法上联合替格瑞洛。检测和比较两组治疗前及治疗4周后心功能指标[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白Ⅰ (cTnⅠ)]，炎症反应指标[肿瘤坏死因子(TNF-α)、单核细胞趋化蛋白-l(MCP-1)、C反应蛋白(CRP)]，凝血功能指标[活化部分凝血酶原时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)、纤维蛋白原(FIB)]及基质金属蛋白酶9(MMP-9)和基质金属蛋白酶12(MMP-12)水平的变化。结果：治疗4周后，两组患者血清CK-MB、cTnⅠ水平、TNF-α、MCP-1、CRP、MMP-9、MMP-12及FIB水平均显著低于治疗前(P＜0.05)，且替格瑞洛组患者以上指标均显著低于对照组(P＜0.05)；两组APTT、PT、TT均显著高于治疗前，且替格瑞洛组以上指标均明显高于对照组(P＜0.05)。结论：替格瑞洛联合联合阿司匹林及瑞舒伐他汀钙片可有效改善冠心病患者的心功能和凝血功能，可能与其有效减轻炎症反应及减少基质金属蛋白酶的含量有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Ticagrelor combined with Risuvastatin calcium tablets and Aspirin on the cardiac function, inflammatory response, blood coagulation and matrix metalloproteinases levels in the patients with coronary heart disease. Methods: Seventy-seven patients with coronary heart disease who were treated in the department of cardiology of our hospital from July 2015 to December 2018 were selected and divided into the Ticagrelor group and control group. Patients in the control group were given aspirin and resuvastatin calcium tablets on the basis of conventional western medicine treatment. Patients in the ticagrelor group were given Ticagrelor on the basis of control group. The myocardial injury index such as creatine kinase isoenzyme (CK-MB), myocardial troponinⅠ (cTnⅠ), inflammation index of tumor necrosis factor (TNF-α), monocyte chemotactic protein -l (MCP-1), c-reactive protein (CRP) and blood coagulation function index activated partial prothrombin time (APTT), prothrombin time (PT), blood enzyme time (TT), fibrinogen (FIB) and matrix metalloproteinase 9 (MMP-9) and matrix metalloproteinases 12 (MMP-12) were detected and compared between two groups before and at 4 weeks after treatment. Results: At 4 weeks after treatment, the levels of serum CK-MB, cTnⅠ, TNF-α, MCP-1, CRP, MMP-9, MMP-12 and FIB in the two groups were significantly lower than those before treatment. And the above indexes in the Ticagrelor group were significantly lower than those in the control group (P<0.05). The APTT, PT, TT in the two groups were significantly higher than those before treatment, and the above indexes in the Ticagrelor group were significantly higher than those in the control group (P<0.05). Conclusion: Ticagrelor combined with aspirin and resuvarastatin calcium tablets can effectively improve the cardiac function and coagulation function in patients with coronary heart disease, which may be related to the effective reduction of inflammatory reaction and the content of matrix metalloproteinases. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
